Qingming Yang

3.9k total citations
62 papers, 2.9k citations indexed

About

Qingming Yang is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Qingming Yang has authored 62 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 17 papers in Pathology and Forensic Medicine and 13 papers in Immunology. Recurrent topics in Qingming Yang's work include CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (17 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Qingming Yang is often cited by papers focused on CAR-T cell therapy research (24 papers), Lymphoma Diagnosis and Treatment (17 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Qingming Yang collaborates with scholars based in China, Philippines and United States. Qingming Yang's co-authors include Weidong Han, Yao Wang, Yelei Guo, Hanren Dai, Kaichao Feng, Zhiqiang Wu, Meixia Chen, Chunmeng Wang, Yang Liu and Chuan Tong and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Qingming Yang

60 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qingming Yang China 20 2.4k 715 704 674 587 62 2.9k
Melvyn T. Chow Australia 16 2.1k 0.9× 862 1.2× 2.2k 3.1× 323 0.5× 231 0.4× 16 3.4k
Yao Yao China 25 1.1k 0.5× 825 1.2× 731 1.0× 193 0.3× 183 0.3× 83 2.2k
Congcong Zhang China 25 1.4k 0.6× 1.1k 1.5× 1.1k 1.6× 337 0.5× 246 0.4× 78 2.8k
Stephan Fricke Germany 18 739 0.3× 705 1.0× 456 0.6× 195 0.3× 142 0.2× 63 1.6k
Kiyoshi Yoshimura Japan 29 1.2k 0.5× 700 1.0× 1.2k 1.7× 120 0.2× 136 0.2× 87 2.4k
Amir Baghbanzadeh Iran 28 808 0.3× 1.1k 1.5× 593 0.8× 236 0.4× 76 0.1× 89 2.3k
Takayuki Ohkuri Japan 22 976 0.4× 583 0.8× 1.5k 2.1× 88 0.1× 87 0.1× 56 2.0k
Na Tang China 17 510 0.2× 456 0.6× 271 0.4× 142 0.2× 143 0.2× 52 1.0k
Shengping Li China 24 680 0.3× 467 0.7× 361 0.5× 148 0.2× 60 0.1× 84 1.7k
Maite G. Fernández‐Barrena Spain 28 1.6k 0.7× 1.6k 2.2× 582 0.8× 164 0.2× 145 0.2× 63 3.2k

Countries citing papers authored by Qingming Yang

Since Specialization
Citations

This map shows the geographic impact of Qingming Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingming Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingming Yang more than expected).

Fields of papers citing papers by Qingming Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingming Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingming Yang. The network helps show where Qingming Yang may publish in the future.

Co-authorship network of co-authors of Qingming Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Qingming Yang. A scholar is included among the top collaborators of Qingming Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingming Yang. Qingming Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Tiance, Jiejie Liu, Yan Zhang, et al.. (2025). Manganese mediates nucleoplasm distribution of cGAS to enhance systemic antitumor immunity and drive abscopal effect. Cancer Letters. 637. 218154–218154.
2.
Liu, Yang, Qingming Yang, Chunmeng Wang, et al.. (2024). The interim analysis of a first-in-human phase 1 trial of ET-901, a CRISPR edited allogeneic immune-cloaked anti-CD19 CAR-T cell therapy in patients with r/r B-NHL.. Journal of Clinical Oncology. 42(16_suppl). e19010–e19010. 2 indexed citations
3.
4.
Wang, Yao, Chuan Tong, Yuting Lu, et al.. (2023). Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduction and Targeted Therapy. 8(1). 409–409. 35 indexed citations
5.
Guo, Yelei, Chuan Tong, Liping Su, et al.. (2022). CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma. Blood Advances. 6(8). 2695–2699. 22 indexed citations
6.
Wang, Chunmeng, Yang Liu, Liang Dong, et al.. (2021). Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy. Clinical Cancer Research. 27(10). 2782–2791. 29 indexed citations
7.
Wang, Yao, Yang Liu, Chuan Tong, et al.. (2021). Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial. Leukemia. 36(1). 189–196. 64 indexed citations
8.
Feng, Kaichao, Yang Liu, Qingming Yang, et al.. (2020). Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. Journal for ImmunoTherapy of Cancer. 8(1). e000367–e000367. 89 indexed citations
9.
Mei, Qian, Wenying Zhang, Yang Liu, et al.. (2020). Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. Clinical Cancer Research. 26(17). 4521–4530. 17 indexed citations
10.
Liu, Yang, Yelei Guo, Zhiqiang Wu, et al.. (2020). Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial. Cytotherapy. 22(10). 573–580. 125 indexed citations
11.
Dai, Hanren, Zhiqiang Wu, Hejin Jia, et al.. (2020). Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of Hematology & Oncology. 13(1). 30–30. 227 indexed citations
12.
13.
Zhang, Wenying, Yang Liu, Yao Wang, et al.. (2018). Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. Gene Therapy. 25(3). 198–204. 7 indexed citations
14.
Guo, Yelei, Kaichao Feng, Yang Liu, et al.. (2017). Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. Clinical Cancer Research. 24(6). 1277–1286. 196 indexed citations
15.
Zhang, Wenying, Yang Liu, Yao Wang, et al.. (2017). Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials. Signal Transduction and Targeted Therapy. 2(1). 17054–17054. 16 indexed citations
16.
Feng, Kaichao, Yelei Guo, Yang Liu, et al.. (2017). Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. Journal of Hematology & Oncology. 10(1). 4–4. 202 indexed citations
17.
Wang, Chunmeng, Zhiqiang Wu, Yao Wang, et al.. (2016). Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clinical Cancer Research. 23(5). 1156–1166. 261 indexed citations
18.
Shen, Bin, Zhanjun Shi, Jianzhong Xu, et al.. (2013). Consensus of Chinese Orthopaedic Experts on Diagnosis and Treatment of Ankylosing Spondylitis. Orthopaedic Surgery. 5(1). 1–5. 4 indexed citations
19.
Cao, Zhigang, et al.. (2013). A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin. Chinese Journal of Cancer. 32(9). 520–523. 4 indexed citations
20.
Zhao, Jianguo, et al.. (2009). Computer-assisted femoral head resurfacing. Journal of Medical Engineering & Technology. 33(1). 9–17. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melvyn T. Chow Breakdown of academic impact, for papers by Yao Yao Breakdown of academic impact, for papers by Congcong Zhang Breakdown of academic impact, for papers by Stephan Fricke Breakdown of academic impact, for papers by Kiyoshi Yoshimura Breakdown of academic impact, for papers by Amir Baghbanzadeh Breakdown of academic impact, for papers by Takayuki Ohkuri Breakdown of academic impact, for papers by Na Tang Breakdown of academic impact, for papers by Shengping Li Breakdown of academic impact, for papers by Maite G. Fernández‐Barrena
Rankless by CCL
2026